Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
Date:3/10/2012

in royalty revenues was in line with our expectations and results from a decline in sales of Thalomid® in the United States.  We will continue to carefully monitor and control expenses and deploy capital in strategic ways."  Further up-to-date information regarding the Company, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, can be found on our web site at www.entremed.com.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently completing a multi-center Phase 2 study in ovarian cancer and completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission (the SEC).

About ENMD-2076ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma.  ENMD-2076 is currently completing a Phase 2 trial for ovarian cancer.

Forward Looking StatementsThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expect
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
2. EntreMed Reports Fourth Quarter and Year-End 2010 Financial Results
3. EntreMed Reports Receipt of Third Quarter Royalty Payment
4. EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
5. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
6. EntreMed to Present at the New York Society of Security Analysts Industry Conference
7. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
8. EntreMed Reports Third Quarter 2008 Financial Results
9. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
10. EntreMed to Present at BioPartnering Europe Conference
11. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of ... 35 th Annual Canaccord|Genuity Growth Conference in ... Chairman and CEO, William C. Taylor , President ...
(Date:8/3/2015)... Aug. 3, 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ... treat life-threatening diseases, today announced that it will host ... webcast on Thursday, August 13, 2015 at 4:30 p.m. ... follow the release of fiscal 2016 first quarter results.  ... approximately two hours after the call at the Investor ...
(Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
(Date:7/31/2015)... , July 31, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... U.S. Securities and Exchange Commission. The filed Form 20-F ... March 31, 2015. The Form 20-F can be accessed ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... ... ... Xybion Corporation announced today that it has completed the acquisition of substantially all of ... The terms of the transactions were not disclosed., , ,Stelex and Vital-Path, based in Bensalem, ...
... CHENGDU, China , May 12 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical ... in the modernized traditional Chinese medicine ("TCM") and branded,generics today announced ... , , Third quarter fiscal year 2010 ending ... revenue increased 60% year over year to $15.9 million, net, ...
... This release is available in French . Physicists ... energy involved in adding electrons to semi-conductor nanocrystals, also known ... and other areas of science. Dr. Peter Grtter, McGill,s Associate ... that his research team has developed a cantilever force sensor ...
Cached Biology Technology:Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare 2Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare 3Tianyin Reports Record Third Quarter 2010 Financial Results 2Tianyin Reports Record Third Quarter 2010 Financial Results 3Tianyin Reports Record Third Quarter 2010 Financial Results 4Tianyin Reports Record Third Quarter 2010 Financial Results 5Tianyin Reports Record Third Quarter 2010 Financial Results 6Tianyin Reports Record Third Quarter 2010 Financial Results 7Tianyin Reports Record Third Quarter 2010 Financial Results 8Tianyin Reports Record Third Quarter 2010 Financial Results 9Tianyin Reports Record Third Quarter 2010 Financial Results 10Tianyin Reports Record Third Quarter 2010 Financial Results 11Tianyin Reports Record Third Quarter 2010 Financial Results 12Tianyin Reports Record Third Quarter 2010 Financial Results 13Quantum move toward next generation computing 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/20/2015)... July 20, 2015  Acuity Market Intelligence,s latest ... Convergence of Commerce and Privacy" forecasts that between ... apps will be downloaded to smart mobile devices ... biometrics market is projected to generate more than ... the seven-year forecast period.    "Biometrics ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... in Oregon,s Willamette Basin to protect at-risk animals won,t ... will absorb more carbon from the atmosphere and vice ... study, to be published this month in the ... hypothetical payments that were given to landowners to voluntarily ...
... UC San Diego are collaborating with scientists from ... map patterns of biodiversity and land use in ... with climate models, will project how climate change ... for setting aside conservation easements. Wildlife, people ...
... Francisco Gonzlez, president of the BBVA Foundation: "One of the ... the environment and, especially, of biodiversity. This is a task ... all play our part. At BBVA, we believe it is ... of the natural resource base" United States researchers ...
Cached Biology News:Incentives for carbon sequestration may not protect species 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 2Biodiversity maps developed by UCSD scientists will help guide conservation measures in East Africa 3BBVA Foundation Awards for Biodiversity Conservation 2BBVA Foundation Awards for Biodiversity Conservation 3BBVA Foundation Awards for Biodiversity Conservation 4
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Mouse monoclonal [TU-20] to beta III Tubulin (FITC) ( Abpromise for all tested applications). entrezGeneID: 10381 SwissProtID: Q13509...
Sheep polyclonal to Methaqualone ( Abpromise for all tested applications). Antigen: Methaqualone(5') conjugated to BSA...
Biology Products: